Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
a terrible situation
bring on some news, some revenues
just more useless tweets today, no BID still
without a Bid, those tweets mean nothing
Carjockey2 yeah man!
congrats to all for another great day!
Agreed, real news on news wires, the real deal
those tweets not news, filings and revenues are news
in 2016 filings they said the same thing
after consolidation, MLCG should move forward nicely
still no bid, and they keep tweeting away
where's the beef? no news, no filings,yield.sign,what.is.going.on?
yes gotta luv it
right PBJT lookin good
solid progress
and the news keeps coming!
been in MLC* since the 0001s, good action
13G was generated on jan 5th but not files until jan 11th
+103% more to come
showtime
49 on the Ask!
looking good so far!
your thoughts?
maybe they got hacked
}}}}}}} $VDRM Bigly news AH, licenses, etc.
13G dated 5th, then dump 125 mil shares till no bid, and then post filing on otcmarkets tonight on the 11th?
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH 5.OLE VOTING POWER
125,267,313 *
1/11/17 SC 13G/A filing >>>>>>
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13G
Under the Securities Exchange Act of 1934
(Amendment No. 1)
Bravatek Solutions, Inc.
(Name of Issuer)
Common Stock
(Title of Class of Securities)
10568D203
(CUSIP Number)
January 5, 2017
(Date of Event which Requires Filing of this Statement)
Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
. Rule 13d-1(b)
X . Rule 13d-1(c)
. Rule 13d-1(d)
* The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.
The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).
CUSIP No. 10568D203 13G
1. NAMES OF REPORTING PERSONS
I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)
LG CAPITAL FUNDING, LLC
46-1906523
2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
(see instructions)
(a) .
(b) X .
3. SEC USE ONLY
4. CITIZENSHIP OR PLACE OF ORGANIZATION
New York
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH 5. SOLE VOTING POWER
125,267,313 *
6. SHARED VOTING POWER
0
7. SOLE DISPOSITIVE POWER
125,267,313 *
8. SHARED DISPOSITIVE POWER
0
*Consists of Common Stock that the reporting person has the right to acquire by way of conversion of a security.
9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
125,267,313 *
*Consists of Common Stock that the reporting person has the right to acquire by way of conversion of a security.
10. CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (see instructions) .
11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
9.899% (based on the total of [ 1,265,447,988 ] outstanding shares of Common Stock)
12. TYPE OF REPORTING PERSON (see instructions)
OO
CUSIP No. 10568D203 13G
Item 1.
(a) Name of Issuer
Bravatek Solutions, Inc.
(b) Address of Issuer’s Principal Executive Offices
2028 E Ben White Blvd.
Suite 240-2835
Austin, TX 78741
Item 2.
(a) Name of Person Filing
LG Capital Funding, LLC
(b) Address of the Principal Office or, if none, residence
1218 Union Street, Suite #2, Brooklyn, NY 11225
(c) Citizenship
New York LLC
(d) Title of Class of Securities
Common Stock
(e) CUSIP Number
10568D203
Item 3. If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a) . Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o).
(b) . Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c).
(c) . Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c).
(d) . Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8).
(e) . An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);
(f) . An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);
(g) . A parent holding company or control person in accordance with §240.13d-1(b)(1)(ii)(G);
(h) . A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i) . A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j) . Group, in accordance with §240.13d-1(b)(1)(ii)(J).
CUSIP No. 10568D203 13G
Item 4. Ownership.
Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.
(a) Amount beneficially owned: 125,267,313 *
(b) Percent of class: 9.899%
(c) Number of shares as to which the person has:
(i) Sole power to vote or to direct the vote 125,267,313 *
(ii) Shared power to vote or to direct the vote
(iii) Sole power to dispose or to direct the disposition of 125,267,313 *
(iv) Shared power to dispose or to direct the disposition of
*Consists of Common Stock that the reporting person has the right to acquire by way of conversion of a security.
Item 5. Ownership of Five Percent or Less of a Class.
If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following . .
Item 6. Ownership of More than Five Percent on Behalf of Another Person.
Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company.
Item 8. Identification and Classification of Members of the Group.
Item 9. Notice of Dissolution of Group.
Item 10. Certification.
(a) The following certification shall be included if the statement is filed pursuant to §240.13d-1(b):
By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.
(b) The following certification shall be included if the statement is filed pursuant to §240.13d-1(c):
By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.
CUSIP No. 10568D203 13G
After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
01/05/2017
Date
/s/ Joseph Lerman
Signature
Managing Member
Name/Title
.05 and more on the way agreed jaco
looks very ready
everything coming together
just some older misc news bits, cool >>>>>>>>>>>>>>
-ViaDerma, Inc. produces TetraStem, a wound care drug that can also treats diabetic foot sores, acne and fight Methicillin-resistant Staphylococcus aureus (MRSA) infections
-LOS ANGELES, Calif. (May 12, 2016) -- ViaDerma, a Los Angeles-based pharmaceutical firm signed a deal with Coast to Coast Podiatry of Reseda to license its products. According to Dr. Chris Otiko, CEO of ViaDerma, the partnership will be beneficial to both companies. “ViaDerma will get our new products in front of patients who need them. And Coast to Coast will have
cutting-edge medicine to help their patients in recovery,” he said.
-May 12, 2016 ViaDerma announces testing on non surgical face-life kit
-May 13, 2016 Testing on toenail antifungal solution begins
-Nov 14, 2016 ViaDerma, Inc. Enters the (MMJ) or Medical Marijuana industry with a Patent Pending CBD Delivery System as California Votes for Expanded Uses of Cannabis. The Treatment Success of ViaDerma's Proprietary Delivery System for Several Diseases by the Efficient and Effective Transdermal Delivery of CBD's & THC to the Localized Treatment Area & into the Blood Stream
-Nov 30, 2016 ViaDerma, Inc. Clinical Studies Abroad in Europe, the Middle East and Asia Show Promising Results & Leads to Private Label Discussions
Clinical Tests Show Dramatic Success of ViaDerma's Proprietary Delivery System Combined with FDA Approved Drugs for Wound Healing with Localized Wound Treatment -- This Leads to Early-Stage discussions with two Pharmaceutical Companies to Private Label Viabecline for Distribution in Europe, Asia, the Middle East, and North Africa
right and VNDM backed off to 005
nice buys rolling in here
absolutely
right, gonna go next week